Advertisement
Screener

Corvus Pharmaceuticals, Inc. (CRVS) Cash Flow Breakdown

2.8 / 5 stars · 68/120 Roast Me

Corvus Pharmaceuticals, Inc. Cash Flow Breakdown

Cash flow breakdown shows where Corvus Pharmaceuticals, Inc.'s cash came from and where it went: from running the business, from investing (buying or selling equipment, companies and investments) and from financing (borrowing, paying back loans, buying back shares, paying dividends). One row per year or quarter. A minus sign means cash went out. Financing is shown line by line: buybacks, dividends, debt paid back, new debt and the rest. All amounts are the filed figures for that period.

  • Fiscal year ended 2025-12-31: from running the business, $32.80M went out.
  • Fiscal year ended 2025-12-31: from investing, $7.80M went out.
  • Fiscal year ended 2025-12-31: from financing, $36.43M came in.
  • Fiscal year ended 2025-12-31: change in cash, $4.16M went out.

A minus sign means cash went out. * = worked out from the filed year-to-date figures (hover to see how); greyed = already counted inside another line.

Each year (12 month)

Fiscal year endRunning the businessFrom investingDividendsNew shares soldNot split outChange in cash
2025-12-31-$32.80M-$7.80M$0.00$684.00K$35.74M*-$4.16M
2024-12-31-$25.42M-$27.48M$0.00$16.41M$32.62M*-$3.88M
2023-12-31-$23.93M$15.54M$0.00$12.00K$7.84M*-$539.00K
2022-12-31-$27.02M-$23.28M-$50.30M
2021-12-31-$36.72M$21.56M$31.99M$30.17M*$47.00M
2020-12-31-$34.78M$44.77M$88.00K$1.22M*$11.30M
2019-12-31-$37.32M$3.25M$24.00K-$34.04M
2018-12-31-$40.99M-$30.19M$64.88M-$5.91M
2017-12-31-$46.21M$84.83M$711.00K$731.00K*$40.06M
2016-12-31-$27.86M-$42.56M$71.35M$945.00K
2015-12-31-$11.33M-$92.03M$108.00K$94.84M*-$8.41M

Each quarter (3 month)

Quarter endRunning the businessFrom investingNew shares soldNot split outChange in cash
2026-06-30-$15.40M*-$5.96M*$0.00*
2026-03-31-$10.37M-$144.85M$189.41M$1.34M*$35.53M
2025-12-31-$9.19M*$10.88M*$20.00K*
2025-09-30-$9.57M*-$2.62M*$360.00K*
2025-06-30-$5.78M*-$20.30M*$25.00K*$35.74M*
2025-03-31-$8.26M$4.24M$279.00K-$3.74M
2024-12-31-$8.46M*-$6.08M*$0.00*$18.61M*
2024-09-30-$6.32M*-$3.89M*$0.00*
2024-06-30-$5.48M*-$17.50M*
2024-03-31-$5.16M-$7.00K-$5.16M
2023-12-31-$5.17M*-$2.32M*$0.00*
2023-09-30-$5.43M*$17.55M*$8.00K*
2023-06-30-$5.22M*-$4.29M*$0.00*$7.52M*
2023-03-31-$8.11M$4.60M$4.00K-$3.50M
2022-12-31-$7.55M*-$3.88M*
2022-09-30-$6.93M*$3.04M*
2022-06-30-$6.12M*$3.14M*
2022-03-31-$6.42M-$25.57M-$32.00M
2021-12-31-$6.86M*-$2.00M*$0.00*
2021-09-30-$8.43M*$3.47M*$0.00*$18.33M*
2021-06-30-$12.65M*$15.24M*$0.00*$11.22M*
2021-03-31-$8.79M$4.85M$31.99M$601.00K*$28.65M
2020-12-31-$8.21M*$463.00K*$1.00K*$1.22M*
2020-09-30-$7.73M*$9.94M*$64.00K*
2020-06-30-$9.49M*$6.67M*
2020-03-31-$9.35M$27.70M$18.34M
2019-12-31-$8.51M*$4.59M*$2.00K*
2019-09-30-$10.61M*-$10.53M*$16.00K*
2019-06-30-$9.21M*$416.00K*$5.00K*
2019-03-31-$8.99M$8.77M$1.00K-$220.00K
2018-12-31-$8.26M*$6.53M*$172.00K*
2018-09-30-$10.80M*$23.31M*$0.00*
2018-06-30-$10.89M*-$63.66M*$0.00*
2018-03-31-$11.04M$3.62M$64.88M$57.46M
2017-12-31-$10.98M*$10.67M*$597.00K*$711.00K*$1.00M*
2017-09-30-$10.77M*$20.66M*$126.00K*$10.01M*
2017-06-30-$11.71M*$35.32M*$0.00*$23.61M*
2017-03-31-$12.75M$18.18M$8.00K$5.44M
2016-12-31-$9.41M*$8.88M*-$1.00K*-$526.00K*
2016-09-30-$6.68M*$7.92M*$0.00*$1.23M*
2016-06-30-$6.13M*-$605.00K*$7.01M*$278.00K*
2016-03-31-$5.64M-$58.75M$64.34M-$40.00K
2015-12-31-$3.94M*-$70.83M*$0.00*-$729.00K*-$75.49M*
2015-09-30-$3.35M*$5.39M*$66.00K*$74.84M*$76.95M*
2015-06-30-$1.71M*-$26.27M*$0.00*$16.73M*-$11.25M*
2015-03-31-$2.32M-$324.00K$42.00K$4.00M*$1.39M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Janux Therapeutics, Inc. (JANX)United States$1.019B-9.15
Pacira BioSciences, Inc. (PCRX)United States$1.020B69.03
Kura Oncology, Inc. (KURA)United States$0.967B-3.29
Arbutus Biopharma Corp (ABUS)$0.965B6.19
MoonLake Immunotherapeutics (MLTX)Switzerland$1.031B-5.43
Savara Inc (SVRA)United States$1.044B-9.10
Jade Biosciences, Inc. (JBIO)United States$0.936B-9.21
MANNKIND CORP (MNKD)United States$1.058B-30.41
Alto Neuroscience, Inc. (ANRO)United States$1.065B-11.02
Apnimed, Inc. (APMD)United States$0.899B